ARNI yields 1000000.00% · ORCC yields 9.79%● Live data
📍 ARNI pulled ahead of the other in Year 1
Combined, ARNI + ORCC cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ARNI + ORCC for your $10,000?
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
Full ARNI Calculator →Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.
Full ORCC Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.